ResearcherUniversity Hospital OlomoucNo recent work listed
Radmila Lemstrová
Matched on ORCID iD 0000-0002-8177-2605; OpenAlex author ID A5010602608. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 37
2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 4 papers · 2018: none · 2019: 1 paper
Papers 7
- Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
- SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
- Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. Co-author DOI 10.1038/tpj.2016.55↗
- Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of th… Co-author DOI 10.3748/wjg.v23.i35.6420↗
- Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. Co-author DOI 10.3892/ol.2017.6946↗
- Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-016-3058-y↗
- Role of solute carrier transporters in pancreatic cancer: a review. Co-author DOI 10.2217/pgs.14.80↗
Closest collaborators
The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Beatrice Mohelníková-Duchoňová · 6 shared papers, 2014–2017 · strength 0.37
- Paper Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer. DOI 10.1007/s00280-016-3058-y↗
- Paper Role of solute carrier transporters in pancreatic cancer: a review. DOI 10.2217/pgs.14.80↗
- Paper Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcino… DOI 10.3748/wjg.v23.i35.6420↗
- Bohuslav Melichar · 4 shared papers, 2014–2017 · strength 0.27
- Paper Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer. DOI 10.1007/s00280-016-3058-y↗
- Paper Role of solute carrier transporters in pancreatic cancer: a review. DOI 10.2217/pgs.14.80↗
- Paper Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcino… DOI 10.3748/wjg.v23.i35.6420↗
- Pavel Souček · 4 shared papers, 2014–2017 · strength 0.21
- Paper Role of solute carrier transporters in pancreatic cancer: a review. DOI 10.2217/pgs.14.80↗
- Paper Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. DOI 10.1038/tpj.2016.55↗
- Paper Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. DOI 10.3892/ol.2017.6946↗
- Martin Oliverius · 3 shared papers, 2017 · strength 0.15
- Paper Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. DOI 10.1038/tpj.2016.55↗
- Paper Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. DOI 10.3892/ol.2017.6946↗
- Paper SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. DOI 10.1038/srep43812↗
- David J. Hughes · 3 shared papers, 2017 · strength 0.15
- Paper Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. DOI 10.1038/tpj.2016.55↗
- Paper Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. DOI 10.3892/ol.2017.6946↗
- Paper SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. DOI 10.1038/srep43812↗
- Zdeněk Kala · 3 shared papers, 2017 · strength 0.15
- Paper Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. DOI 10.1038/tpj.2016.55↗
- Paper Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. DOI 10.3892/ol.2017.6946↗
- Paper SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. DOI 10.1038/srep43812↗
- R Havlík · 2 shared papers, 2017 · strength 0.11
- Martin Loveček · 2 shared papers, 2017 · strength 0.11
- Jan Hlavsa · 2 shared papers, 2017 · strength 0.11
- Dušan Klos · 1 shared paper, 2017 · strength 0.06
- Viktor Hlaváč · 1 shared paper, 2017 · strength 0.05
- Paola Fogar · 1 shared paper, 2017 · strength 0.04
- Gianfranco Delle Fave · 1 shared paper, 2017 · strength 0.04
- Giuseppe Malleo · 1 shared paper, 2017 · strength 0.04
- Nathalia A. Giese · 1 shared paper, 2017 · strength 0.04
- Andrea Mambrini · 1 shared paper, 2017 · strength 0.04
- Maria Gazouli · 1 shared paper, 2017 · strength 0.04
- Maurizio Cantore · 1 shared paper, 2017 · strength 0.04
- Federico Canzian · 1 shared paper, 2017 · strength 0.04
- Niccola Funel · 1 shared paper, 2017 · strength 0.04
- Sergio Pedrazzoli · 1 shared paper, 2017 · strength 0.04
- Roberto Valente · 1 shared paper, 2017 · strength 0.04
- Thilo Hackert · 1 shared paper, 2017 · strength 0.04
- Cosimo Sperti · 1 shared paper, 2017 · strength 0.04
- Ľudmila Vodičková · 1 shared paper, 2017 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.